产品说明书

Moxifloxacin HCl

Print
Chemical Structure| 186826-86-8 同义名 : 莫西沙星盐酸盐 ;BAY 12-8039;Moxifloxacin (hydrochloride);Moxifloxacin Hydrochloride
CAS号 : 186826-86-8
货号 : A250011
分子式 : C21H25ClFN3O4
纯度 : 98%
分子量 : 437.892
MDL号 : MFCD00949117
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 25 mg/mL(57.09 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 15 mg/mL(34.25 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Moxifloxacin is an oral 8-methoxyquinolone antimicrobial that is used in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[3]. The antibacterial spectrum of moxifloxacin includes all major upper and lower respiratory tract pathogens[4]. Concentrations of mocifloxacin equal to and greater than the MIC (range 0.125 to 1μg/ml) prevented the formation of filopodium-like projections, and changes in the morphological aspects of the intracellular bacteria. It is also appeared to have a protective effect against macrophage lysis, as many cells were still viable after 24h of incubation[5]. Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.42mL

2.28mL

1.14mL

22.84mL

4.57mL

2.28mL
参考文献

[1]Dhillon V, Chaudhary AK. A validated HPTLC method for estimation of moxifloxacin hydrochloride in tablets. Pharm Methods. 2010 Oct;1(1):54-6.

[2]Cruz LA, Hall R. Enantiomeric purity assay of moxifloxacin hydrochloride by capillary electrophoresis. J Pharm Biomed Anal. 2005 Jun 1;38(1):8-13.

[3]Culley CM, Lacy MK, Klutman N, Edwards B. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm. 2001;58(5):379-388.

[4]Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000;59(1):115-139.

[5]Grayo S, Join-Lambert O, Desroches MC, Le Monnier A. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008;52(5):1697-1702.

[6]Ioannidis O, Papaziogas B, Tsiaousis P, Paraskevas G, Giamarellos-Bourboulis EJ, Koutelidakis I. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014;58(2):96-102.